25 completed. 25 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 25 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIa Study in Primary IgA Nephropathy Patients XH-S003 Capsule - IgA Nephropathy | Phase 2 | Completed | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 25 | 2024-12-31 | 2026-09-25 |
| Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN Placebo, HSK39297 50mgBID, HSK39297 100mgBID - IgA Nephropathy (IgAN) | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 87 | 2024-10-12 | 2026-05-28 |
| A Trial of HRS-5965 Tablets in Primary IgA Nephropathy HRS-5965, Placebo - Primary IgA Nephropathy | Phase 2 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 123 | 2023-12-19 | 2026-07-24 |
| Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy Atrasentan, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 2 | Completed | Novartis Pharmaceuticals | 54 | 2023-07-20 | 2026-07-20 |
| A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Sparsentan - Immunoglobulin A Nephropathy | Phase 2 | Completed | Travere Therapeutics, Inc. | 48 | 2023-05-19 | 2025-11-20 |
| Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease ARO-C3, Placebo - C3 Glomerulopathy, IgA Nephropathy | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 62 | 2022-02-01 | 2026-05-22 |
| A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. HR19042 Capsules, Placebo - IgA Nephropathy | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 316 | 2021-09-09 | 2026-03-12 |
| Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy Felzartamab, Placebo - Immunoglobulin A (IgA) Nephropathy | Phase 2 | Completed | HI-Bio, A Biogen Company | 54 | 2021-08-31 | 2026-04-28 |
| Safety and Efficacy Study of VIS649 for IgA Nephropathy Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649 - Immunoglobulin A Nephropathy, Glomerular Disease | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 155 | 2020-07-20 | 2026-04-24 |
| A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy RC18 160mg, RC18 240mg, placebo - Primary IgA Nephropathy | Phase 2 | Completed | RemeGen Co., Ltd. | 44 | 2020-04-13 | 2024-09-19 |
| A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy IONIS-FB-LRx - Primary IgA Nephropathy | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 23 | 2019-12-04 | 2025-01-23 |
| Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses - IgA Nephropathy | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 103 | 2019-04-08 | 2026-06-16 |
| Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies APL-2 - IgA Nephropathy, Lupus Nephritis | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 21 | 2018-02-26 | 2025-02-13 |
| Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation LNP023, Placebo - IgA Nephropathy | Phase 2 | Completed | Novartis Pharmaceuticals | 112 | 2018-02-07 | 2023-01-30 |
| A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX Bardoxolone methyl capsules - IgA Nephropathy, CKD Associated With Type 1 Diabetes | Phase 2 | Completed | Biogen | 103 | 2017-12-26 | 2025-06-03 |
| Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade CCX168 - Immunoglobulin A Nephropathy | Phase 2 | Completed | Amgen | 7 | 2015-03-27 | 2025-03-13 |
| Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy Fostamatinib 150 mg, Fostamatinib 100 mg, Placebo - IGA Nephropathy | Phase 2 | Completed | Rigel Pharmaceuticals | 76 | 2014-10-01 | 2019-06-27 |
| BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration Blisibimod, Placebo - IgA Nephropathy | Phase 2 / Phase 3 | Completed | Anthera Pharmaceuticals | 57 | 2013-06-01 | 2017-09-18 |
| The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease NEFECON, Placebo - Primary IgA Nephropathy | Phase 2 | Completed | Calliditas Therapeutics AB | 150 | 2012-12-01 | 2015-09-24 |
| A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients Tacrolimus, Placebo - IgA Nephropathy | Phase 2 | Completed | Astellas Pharma Inc | 40 | 2010-11-01 | 2014-08-21 |
Showing 20 of 25. Sign in to see all of them.
Kidney Diseases (6) · Diabetes Mellitus (2) · Diabetic Nephropathies (2) · Glomerulonephritis (2) · Hypertension (2) · Hypertension, Renal (2) · Kidney Failure, Chronic (2) · Renal Insufficiency, Chronic (2) · Urologic Diseases (2) · Autoimmune Diseases (1) · Glomerulonephritis, Membranoproliferative (1) · Glomerulonephritis, Membranous (1) · Glomerulosclerosis, Focal Segmental (1) · Immune System Diseases (1)
Female Urogenital Diseases (25) · Female Urogenital Diseases and Pregnancy Complications (25) · Male Urogenital Diseases (25) · Autoimmune Diseases (24) · Immune System Diseases (24) · Nephritis (24) · Urogenital Diseases (24) · Glomerulonephritis (23) · Urologic Diseases (23) · Kidney Diseases (19) · Pathological Conditions, Signs and Symptoms (6) · Disease Attributes (5) · Pathologic Processes (5) · Chronic Disease (4) · Renal Insufficiency (4)
Mycophenolic Acid (2) · AMG623 peptibody (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Anti-Inflammatory Agents (1) · Atrasentan (1) · Budesonide (1) · Fatty Acids, Omega-3 (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Omacor (1) · Prednisone (1) · RC-18 (1) · Rituximab (1) · Sirolimus (1) · Tacrolimus (1) · avacopan (1)
Novartis Pharmaceuticals (3) · Calliditas Therapeutics AB (2) · University of Washington (2) · Amgen (1) · Anthera Pharmaceuticals (1) · Apellis Pharmaceuticals, Inc. (1) · Arrowhead Pharmaceuticals (1) · Astellas Pharma Inc (1) · Biogen (1) · Chengdu Suncadia Medicine Co., Ltd. (1) · HI-Bio, A Biogen Company (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Ionis Pharmaceuticals, Inc. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Josep m Cruzado (1)
United States (11) · South Korea (8) · United Kingdom (7) · Australia (6) · China (6) · Germany (6) · Hong Kong (5) · Malaysia (5) · Spain (5) · Taiwan (5) · Czechia (4) · Singapore (4) · Sweden (4) · Thailand (4) · Belgium (3)
Connie L Davis, MD (2) · Alex Mercer, PhD (1) · Asher Schachter, M.D. (1) · Hong Zhang, M.D. (1) · Josep M Cruzado, Medical Doctor (1) · Meritxell Ibernon, MD (1) · Radko Komers, MD, PhD (1) · Ronald Hogg (1)
PMID 38299639, PMID 26032537, PMID 17699247, PMID 23977072, PMID 28363480, PMID 30177021, PMID 34124781, PMID 37036696, PMID 37772889, PMID 37916620, PMID 38008160, PMID 39331470, PMID 40444214, PMID 40465397, PMID 40482854, PMID 40581166, PMID 41408192, PMID 41443406, PMID 41904616, PMID 42275148
2014 (2), 2023 (2), 2005 (1), 2017 (1), 2018 (1), 2019 (1), R01DK049368 (1)